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Abstract
Hereditary hemochromatosis (HH) is a genetic iron overload disease, in the majority of cases associated with homozygosity for the
C282Y mutation of the HFE gene. In spite of this genetic homogeneity, there is a great clinical heterogeneity among HH patients. Low
CD8+ lymphocyte numbers have been associated with a more severe expression of iron overload in HH patients, and in experimental
models of iron overload. HH patients present low serum transferrin levels. Transferrin is an indispensable resource for lymphopoiesis.
Lymphocyte homeostasis follows general ecology rules of population dynamics that involve competition for limiting resources. In the
present study, we questioned whether transferrin levels could be associated with the anomalies seen previously in lymphocyte subset
numbers in HH patients. Transferrin levels, total and subset T lymphocyte counts were done in 426 apparently healthy subjects genotyped
for HFE. All HFE C282Y carriers presented significantly lower serum transferrin levels than the wild type group, a difference that could
not be explained solely by the degree of iron overload. Significant differences were also seen in transferrin levels between males and
females, with females presenting higher average serum Transferrin levels. In the population of subjects with Transferrin levels lower than
248 mg/dl, a positive correlation was seen between the peripheral CD8+ lymphocyte numbers and serum transferrin levels (R2 = 2.41; r =
0.16; P = 0.018). To test the possible limiting resource effect of transferrin, the correlation between transferrin levels and CD8+
lymphocyte numbers was scrutinized in 34 HH patients, homozygous for the C282Y mutation. In the homozygous males, where the
lowest average transferrin levels were seen, another highly significant correlation was observed between Transferrin levels and CD8+
numbers. This correlation points to a possible role of transferrin as a limiting resource for MHC class I dependent lymphocyte
proliferation, an effect that was not observed in C282Y homozygous female patients.
D 2005 Elsevier Inc. All rights reserved.
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Introduction
Hereditary hemochromatosis (HH), a genetic iron-over-
load disease, is associated with HFE, a gene that codes for a
non-classical MHC class I protein [1]. In spite of the fact
that one mutation, the C282Y, is found in homozygozity in
the majority of Caucasian patients, there is a great clinical
heterogeneity in expression of the resulting iron overload
[2–4]. The severity of iron overload assessed by iron
removed by phlebotomy, serum ferritin and Transferrin
(Trf) saturation, is consistently greater in men than in
women [5–7]. Low CD8+ T and/or total lymphocyte
numbers have been reported to correlate significantly with
higher iron stores in HH [4,8–10]. Selective abnormalities
in CD8+ T lymphocytes have been consistently described in
HH patients. These include a defective p56-lck kinase
activity, decreased cytotoxic activity, a decreased number of
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CD8+ T cells expressing the CD28 molecule, abnormalities
in the T cell receptor repertoire and cytokine production
[11–14]. In addition, studies of double knockout mice
indicate that the iron load in Hfe/ mice is higher when
crossed to h2m/ [15] or to Rag1/[16].
Lymphocyte homeostasis follows general ecology
rules of population dynamics that involve competition for
limiting resources [17]. Trf is a well-known resource for the
growth of numerous cell types including lymphocytes [18–
20]. Moreover, anti-Trf receptor antibodies inhibit lympho-
cyte and thymocyte proliferation and differentiation in vitro
[21,22]. Quimeric animals for a deletion in the Trf receptor
gene revealed the importance of the Trf receptor for the
differentiation of bone marrow hematopoietic precursors
into erythroid and thymus dependent lymphoid lineages
[23]. The hypotransferrinemic mice permitted to go further
dissecting the role of Trf in hematopoiesis. These animals
present a defective T cell differentiation at a specific early
stage, during the thymocyte differentiation from TN3 to the
TN4 stage [24]. The same specific defect was observed in
mice heterozygotes for the Trf receptor 1 deficiency,
indicating that the Trf dependent thymus effect is mediated
by its receptor [24].
Abnormally low serum Trf levels are commonly observed
in C282Y homozygous subjects [25,26]. These are generally
attributed to the effect of severe iron overload, in contrast
with the finding of increased serum Trf concentration in iron
deficiency [27]. Decreased Trf values were also reported in
large populations of C282Y carriers with iron parameters
within the normal range [25 26]. The objective of the present
study was threefold: (1) to examine Trf levels in a large
apparently healthy population of 426 HFE genotyped
subjects; (2) to examine the existence of possible associations
between lymphocyte numbers and Trf in groups selected for
distinct average Trf serum levels and (3) to examine the same
question in a group of 34 C282Y homozygous HH patients.
Material and methods
Population Studied
C282Y homozygous HH patients
Thirty-four hereditary hemochromatosis (HH) patients
homozygous for the C282Y mutation of the HFE gene were
included in this study. Patients are regularly followed up at
the Hemochromatosis Outpatient Clinic of Santo Anto´nio
General Hospital, Porto. Nineteen were males (mean age
47 T 14) and 15 were females (mean age 44 T 13). All
patients had Trf saturation greater than 50% at the time of
the diagnosis. Patients are regularly treated by weekly
phlebotomy (intensive treatment) until iron depletion is
achieved (Trf saturation below 10% and/or ferritin levels
below 10 ng/ml). After intensive treatment, patients are
phlebotomized between 4 and 12 times per year, depending
on individual profile (maintenance treatment) [9]. Because
of the impact of liver disease on Trf levels, patients with
cirrhosis and/or any degree of fibrosis in liver biopsy were
excluded.
Healthy population
Four hundred and twenty-six apparently healthy subjects
previously studied as part of the routine screening program
for hemochromatosis at the Hemochromatosis Outpatient
Clinic of Santo Anto´nio General Hospital and Predictive
and Preventive Genetic Center (IBMC), Porto, were also
analyzed. These include 279 family members of HH pa-
tients with no evidence of iron overload or other related
pathologies, and 147 unrelated normal subjects. This
healthy population included 181 males (mean age 40 T
15) and 245 females (mean age 44 T 15). All subjects had
been previously HFE genotyped as described before [28].
Exclusion criteria for the healthy population study were age
<20 years old and evidence of viral infection (HBV, HCV,
HTLV, HIV1 and HIV2).
Clinical and laboratory parameters included in this work
were reviewed from the clinical files or determined in the
course of the present study, with the informed consent of the
subjects according to the Helsinki declaration. Clinical and
laboratory data from the present study population have been
previously published [4,9,13,28].
A final group of 10 subjects with previously detected Trf
saturation lower than 20% was used as controls to establish
reference values for serum Trf levels in iron deficient
conditions.
Biochemical and hematological parameters
Biochemical parameters of iron metabolism (serum iron,
serum Trf, Trf saturation and serum ferritin) and hemo-
globin were routinely determined in the Clinical Chemistry
and Hematology Laboratories of Santo Anto´nio General
Hospital, Porto by standard techniques. Serum iron was
analyzed in a Cobas INTEGRA 800 Analyzer (Roche,
Switzerland). Serum ferritin and Trf were determined by
immunoturbidimetric tests in the same Analyzer. Trf
saturation was calculated from the formula: (serum iron 
100) / (serum Trf  1.41).
Peripheral blood T cell phenotyping
Total lymphocyte counts were determined in an auto-
matic blood cell counter (Coulter Gen S). Leukocytes were
stained from samples of freshly collected peripheral blood.
A volume of 3 ml of whole blood was fixed with an equal
volume of formaldehyde (0.4%) for 4 min at 37-C. The red
blood cells were then lysed with 50 ml of lyses solution
(10 mM Tris, 0.15 M NH4Cl, pH 7.4) for 10 min at 37-C.
Cells were washed twice in phosphate-buffered saline (PBS)
supplemented with 0.2% bovine serum albumin (BSA) and
0.1% sodium azide (PBS-BSA). After the final wash,
approximately 5  106 cells were stained in round-bottom
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96-well plates (Greiner-Nurtingen, Germany), at 4-C for
30 min in the dark. The following monoclonal antibodies
(moABs) were used: CD3-PerCP, CD4-PE and CD8-FITC
(Dako, Copenhagen, Denmark). After the staining, cells
were washed twice with PBS-BSA and fixed in a final
volume of 500 Al with PBS containing 0.1% paraformalde-
hyde. At least 2  104 lymphocytes were acquired in a
FACScan (Becton Dickinson, San Jose, CA, USA) and
analyzed using the Lysis II or Cell Quest programs
(Becton Dickinson, San Jose, CA, USA). Percentages of
CD3+CD4+and CD3+CD8+ cells within the lymphocyte
population were obtained. The absolute numbers of
CD4+(CD3+CD4+) and CD8+(CD3+CD8+) lymphocytes
were then calculated from the total lymphocyte counts by
the formula: CD4+(or CD8+) cells = %CD3+CD4+(or
CD3+CD8+)  total lymphocyte counts ( 106/ml) / 100.
Statistical methods
For the purpose of statistical analysis, subjects were
divided according to the HFE genotype. All values tested
represent the results obtained at diagnosis, unless otherwise
stated. Group means were compared by the one-way
analysis of variance test (ANOVA). Multiple comparisons
were performed using the Scheffe test. Student’s t test was
used whenever comparisons were done between two groups.
Trf longitudinal study
Serial data from 16 hemochromatosis patients regularly
treated at the Hemochromatosis Outpatient Clinic were used
for Trf longitudinal studies. Serum iron Trf and hemoglobin
levels were measured regularly from the beginning to the
end of the intensive treatment and for at least 2 years
thereafter. Presentation of results (Fig. 1A) was done by
calculating the average of serum iron and Trf as well as
hemoglobin levels at diagnosis, one third and two thirds of
the intensive treatment period, at the end of intensive
treatment and 6 months, 1 and 2 years after the end of the
intensive treatment.
Trf versus lymphocyte numbers
The relationship between Trf and lymphocyte popula-
tions was assessed by regression analysis. In addition, a
stepwise multiple regression model was used to test the
relative impact of other iron related variables, namely Trf
saturation, serum iron and serum ferritin, on CD8+ T
lymphocyte numbers. Data were analyzed by Statgraphics
software (Statgraphics Graphics System, version 7.0).
Results
Serum Trf and HFE mutations
A summary of iron biochemical parameters according to
gender and HFE genotypes is shown in Table 1. As
expected, serum iron and Trf saturation were higher in all
HFE mutation groups in both genders. Serum Trf levels
were significantly lower in all C282Y carriers in comparison
to HFE wild type subjects, both in males and females. The
lowest average values were observed in the groups of
C282Y homozygous (180 T 32 in males and 191 T 36 in
females). In all groups analyzed, serum Trf levels are higher
in females than in males (Table 1).
In order to evaluate the impact of iron burden on Trf
values, a serial analysis of serum Trf was performed in 16
C282Y homozygous HH patients during the course of
phlebotomy treatment (Fig. 1A). In all cases, Trf serum
values are low and do not change significantly with the
diminishing serum iron levels during the course of
intensive phlebotomy treatment. The end of the intensive
Fig. 1. Variation of serum Trf, iron and hemoglobin levels in C282Y
homozygous subjects during the course of intensive and maintenance
phlebotomy treatment. (A) Average of Trf, iron and hemoglobin (Hgb)
levels (n = 16) at 7 time points during phlebotomy treatment: (1) diagnosis;
(2) one third of the intensive treatment period; (3) two thirds of the
intensive treatment period; (4) end of intensive treatment; (5) 6 months after
the end of the intensive treatment; (6) 1 year after the end of the intensive
treatment; (7) 2 years after the end of the intensive treatment.
(B) Representative example out of 16 cases studied. Characteristic
Trf values of non-hemochromatosis subjects with iron deficiency 368 T 45.
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treatment in the protocol used is characterized by a
decrease in hemoglobin (Hgb) due to iron deficient
erythropoiesis. At this point, serum iron levels drop and
Trf concentration peaks (see Fig. 1A), but average Trf
(268 T 49) never attains levels comparable to those seen in
iron deficient subjects (368 T 45) at comparable low Trf
saturation levels (<20%). During maintenance, lasting on
average more than 2 years, Trf levels drop again to levels
significantly lower than the ones observed in wild type
subjects (P = 0.00001). A representative individual
example is given in Fig. 1B.
Serum Trf and lymphocyte numbers
When the overall, male and female, population was
analyzed, no correlation could be found between serum Trf
levels and lymphocyte numbers (both total lymphocyte and
CD8+ or CD4+ T lymphocytes). If Trf acts as a limiting
resource, however, one could expect that a result would
only be seen in the subjects with the lower Trf values.
Thus, the population studied was divided into two
subpopulations, including males and females according to
serum Trf levels. A statistically significant positive
correlation was observed between serum Trf and CD8+
lymphocyte numbers for Trf levels less or equal to
248 (median of the Trf levels of the studied population)
(Fig. 2A; R2 = 2.41; r = 0.16; P = 0.018; n = 233). No
correlation was found between Trf values higher than
248 and CD8+ lymphocyte numbers (Fig. 2B). No
correlation was observed for the CD4+ or total lymphocyte
numbers (data not shown). In order to clarify the possible
effect of other iron related variables in the correlation
found between Trf and CD8+ T lymphocyte numbers, a
stepwise multiple regression model was run taking as
dependent variable the CD8+ T lymphocyte numbers and
as independent variables, besides Trf, Trf saturation, serum
ferritin and serum iron. The only variable entering this
model was Trf (F = 6.93; P = 0.00372). To confirm
further a limiting effect of Trf in the CD8+ T lymphocyte
numbers, the subpopulation with the lowest Trf levels
namely, male subjects homozygous for the C282Y
mutation (Trf: 180 T 32, Table 1), was also examined. A
highly significant positive correlation was observed
between serum Trf and CD8+ lymphocyte numbers
Fig. 2. Regression of CD8+ lymphocyte numbers with serum Trf levels in:
(A) subjects with Trf values  248; (B) subjects with Trf values > 248;
(C) male HH subjects C282Y homozygous.
Table 1
Iron biochemistry according to HFE genotype and gender
HFE genotype Males Females
n Age Fe
(Ag/dl)
TrfSat
(%)
Ferritin
(ng/ml)
Trf
(mg/dl)
n Age Fe
(Ag/dl)
TrfSat
(%)
Ferritin
(ng/ml)
Trf
(mg/dl)
C282Y/C282Y 19 47 T 14 213 T 37a 89 T 13a 1658 T 455a 180 T 32a 15 44 T 13 192 T 44a 79 T 15a 225 T 79a 191 T 36a
C282Y/wt 53 36 T 13 113 T 32 35 T 11a 128 T 19 233 T 36a 77 41 T 15 94 T 36 27 T 12a 46 T 7 257 T 44a
C282Y/H63D 12 42 T 18 142 T 39a 50 T 17a 180 T 16 211 T 36a 13 43 T 16 118 T 31a 38 T 9a 35 T 17 224 T 34a
H63D/wt 48 44 T 16 118 T 46a 35 T 14a 127 T 22 245 T 25 60 49 T 14 96 T 35 27 T 12 48 T 14 263 T 42a
H63D/H63D 12 47 T 15 149 T 31a 47 T 18a 167 T 80 242 T 51 6 47 T 15 109 T 21 32 T 11 27 T 26 252 T 47
Wt/wt 56 40 T 13 100 T 35 29 T 11 113 T 22 253 T 36 89 44 T 15 89 T 31 23 T 9 34 T 9 278 T 49
P (ANOVA) 0.0265 <0.0000 <0.0000 <0.0000 <0.0000 0.0634 <0.0000 <0.0000 <0.0000 <0.0000
Mean T standard deviation for all parameters except serum ferritin, which is geometric mean T standard error.
a Statistically significant differences between groups of subjects carriers of HFE mutations and the group without HFE mutations by the multiple range
analysis.
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(Fig. 2C, R2 = 28.9; r = 0.54; P = 0.017). No significant
correlations were found, however, between Trf values and
either CD4+ or total lymphocyte numbers or in females
(data not shown).
Discussion
The question of genotype–phenotype discrepancies in
HFE hemochromatosis has been the subject of considerable
discussion [29–32]. Both from clinical and specifically
from experimental work, there is mounting evidence that
low CD8+ T lymphocytes could act as indicators of severe
iron overload expression [4,8–10,13,14]. Several animal
models of increased iron absorption with defective CD8+ T
cell or total lymphocyte numbers have demonstrated the
modifier effect of those cells in the severity of iron overload,
namely single or double knockout mice (MHC class I/;
h2m/Rag1/; Hfe/Rag1/; Hfe/h2m/)
[15,16,33]. CD8+ knockout mice alone do not develop
spontaneous iron overload [33]. A more probable link might
involve MHC class I expression itself [33,34]. No clues
have been offered so far to explain the modifying effect of
CD8+ cells in iron overload in humans or explain the lack of
correlations seen in females. There is growing evidence,
both in human and animal models, that the numbers of
lymphocytes are genetically determined [28,35–41]. Recent
work has shown that the MHC class I genetic region is
involved in this regulation [28]. Other nutritional but at
present unidentified factors may be involved that might
contribute to the persistent failure to observe any correlation
between lymphocyte numbers and iron stores in homozy-
gous female patients.
Trf, however, is a well-known resource for the prolifer-
ation of numerous cell types including lymphocytes [20,21].
The effect of a limited resource in vivo in lympho-
cyte numbers is compatible with the statistically significant
positive correlation between serum Trf and numbers of
circulating CD8+ cells for subjects with Trf levels lower
than 248 mg/dl, described in this paper. Male patients
homozygous for the C282Y mutation consistently present
lower levels of serum Trf in comparison to female patients.
Therefore, it is reasonable to assume that if Trf acts as a
limiting factor for lymphocyte numbers, this effect would be
particularly manifested in this subgroup. This was the case.
It remains unsubstantiated and unexplained in the female
patient group. The significantly higher serum Trf levels seen
in females, however, may help to explain the differences in
iron overload expression between males and females [5–7].
Surprisingly, no correlation between serum Trf levels and
CD4+ or total lymphocyte numbers was seen. Such a result
brings to light once more the involvement of MHC class I in
this disorder [10,28,33]. CD8+ but not CD4+ T lymphocytes
are activated and proliferate in the context of MHC class I
molecules (reviewed in [17]). Recent results of a separate
study of MHC class I expression in C282Y homozygous
patients show that the mutant C282Y HFE peripheral blood
mononuclear cells fail to express MHC class I as abundantly
as cells from wild type subjects [34].
The lower serum Trf values observed in the C282Y HFE
mutant groups could be a result of decreased Trf synthesis.
It is classically assumed that this could be due to down-
regulation evoked by iron overload. It does not explain,
however, the finding that the decreased levels found in HH
patients do not correct after treatment. Moreover, lower
mean values of Trf are found also in C282Y carriers,
without severe iron overload, as shown here and before by
other groups [25,26]. HFE itself could mediate this effect.
We would like to consider, however, an additional explan-
ation. Trf has been shown sometime ago to circulate from
the extracellular pool to the ‘‘interstitial fluid pool’’ and
enter the lymph [27]. Passage to the lymph of serum
proteins was thought to depend exclusively on protein
molecular weight [42] at a time when Trf receptors had not
been discovered [27]. More recent work has demonstrated
that murine brain and lymph node derived endothelial cell
lines have receptors for Trf. The lymph node endothelial cell
line was shown to have twice as many Trf receptors as brain
derived endothelium [43]. Trf traffic seems therefore to
coincide with lymphocyte traffic from blood to lymph [44].
The lymph nodes provide a preferred environment for
lymphocyte growth and division restricted in the case of
CD8+ lymphocytes by MHC class I alleles. This could
provide an explanation for the apparent preferential corre-
lation found in this and previous reports [8,9] of low CD8+
rather than CD4+ cells with severity of iron overload.
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